BC
MLTX icon

Birchview Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Birchview Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8,000
Closed -$378K – 75
2025
Q2 		$378K Hold
8,000
– – 0.38% 46
2025
Q1 		$313K Buy
8,000
+4,000
+100% +$172K 0.27% 43
2024
Q4 		$217K Buy
+4,000
New +$204K 0.18% 56

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Birchview Capital's MLTX Position: Q3 2025 in Review

Birchview Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 8,000 shares — an estimated $378K sold.

Birchview Capital first reported a position in MLTX in Q4 2024 and held it in 3 quarters. The position peaked at $378K in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Birchview Capital reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Birchview Capital sold 8,000 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $378K.
  • Birchview Capital first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 3 quarters.
  • Birchview Capital's MoonLake Immunotherapeutics position peaked at $378K in Q2 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Birchview Capital's 13F filing for Q3 2025, filed 13 Nov 2025.